Glimepiride/pioglitazone

Anti-SPG11 spastic paraplegia 11 (autosomal recessive), 25ul

Anti-SPG21 spastic paraplegia 21 (autosomal recessive, Mast

Anti-SPG21 spastic paraplegia 21 (autosomal recessive, Mast

Anti-WEE1 WEE1 G2 checkpoint kinase, 100ul UN 1687 6.1 PG2

AP470-001A SPRAY HEAD ASSY GS-PLUS

DescriptionAPhos Pd G4 is a powerful ligand for classic cross-coupling reactions combined with theBuchwaldFourth Generation Palladacycle. Bench stable, soluble in most organic solvents.

DescriptionAPhos Pd G4 is a powerful ligand for classic cross-coupling reactions combined with theBuchwaldFourth Generation Palladacycle. Bench stable, soluble in most organic solvents.

D,L-Aminogluthethimide is an inhibitor of aromatase and adrenal steroid synthesis that exhibits immunosuppressive and anticancer chemotherapeutic activities. This compound is used to treat breast cancer and Cushing’s disease.

D,L-Aminogluthethimide is an inhibitor of aromatase and adrenal steroid synthesis that exhibits immunosuppressive and anticancer chemotherapeutic activities. This compound is used to treat breast cancer and Cushing’s disease.

AS2717638 is an oral active and selective lysophosphatidic acid receptor 5 (LPA5) antagonist, with an IC 50 of 38 nM for hLPA5. AS2717638 also significantly improves PGE 2 -, PGF 2α -, and AMPA-induced allodyniaForm:SolidIC50&amp: Target:IC50: 38 nM

AS2717638 is an oral active and selective lysophosphatidic acid receptor 5 (LPA5) antagonist, with an IC 50 of 38 nM for hLPA5. AS2717638 also significantly improves PGE 2 -, PGF 2α -, and AMPA-induced allodyniaForm:SolidIC50&amp: Target:IC50: 38 nM

AS2717638 is an oral active and selective lysophosphatidic acid receptor 5 (LPA5) antagonist, with an IC 50 of 38 nM for hLPA5. AS2717638 also significantly improves PGE 2 -, PGF 2α -, and AMPA-induced allodyniaForm:SolidIC50&amp: Target:IC50: 38 nM